437 related articles for article (PubMed ID: 18922969)
1. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.
Ilvesaro JM; Merrell MA; Li L; Wakchoure S; Graves D; Brooks S; Rahko E; Jukkola-Vuorinen A; Vuopala KS; Harris KW; Selander KS
Mol Cancer Res; 2008 Oct; 6(10):1534-43. PubMed ID: 18922969
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity.
Merrell MA; Ilvesaro JM; Lehtonen N; Sorsa T; Gehrs B; Rosenthal E; Chen D; Shackley B; Harris KW; Selander KS
Mol Cancer Res; 2006 Jul; 4(7):437-47. PubMed ID: 16849519
[TBL] [Abstract][Full Text] [Related]
3. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro.
Ilvesaro JM; Merrell MA; Swain TM; Davidson J; Zayzafoon M; Harris KW; Selander KS
Prostate; 2007 May; 67(7):774-81. PubMed ID: 17373717
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 9 ligands enhance mesenchymal stem cell invasion and expression of matrix metalloprotease-13.
Nurmenniemi S; Kuvaja P; Lehtonen S; Tiuraniemi S; Alahuhta I; Mattila RK; Risteli J; Salo T; Selander KS; Nyberg P; Lehenkari P
Exp Cell Res; 2010 Oct; 316(16):2676-82. PubMed ID: 20553713
[TBL] [Abstract][Full Text] [Related]
5. Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88.
Senn JJ; Burel S; Henry SP
J Pharmacol Exp Ther; 2005 Sep; 314(3):972-9. PubMed ID: 15919763
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 9 mediates CpG-DNA signaling.
Chuang TH; Lee J; Kline L; Mathison JC; Ulevitch RJ
J Leukoc Biol; 2002 Mar; 71(3):538-44. PubMed ID: 11867692
[TBL] [Abstract][Full Text] [Related]
7. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
[TBL] [Abstract][Full Text] [Related]
8. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.
Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G
J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228
[TBL] [Abstract][Full Text] [Related]
9. Human lung cancer cells express functionally active Toll-like receptor 9.
Droemann D; Albrecht D; Gerdes J; Ulmer AJ; Branscheid D; Vollmer E; Dalhoff K; Zabel P; Goldmann T
Respir Res; 2005 Jan; 6(1):1. PubMed ID: 15631627
[TBL] [Abstract][Full Text] [Related]
10. CpG oligonucleotides induce an immune response of odontoblasts through the TLR9, MyD88 and NF-kappaB pathways.
He W; Yu Q; Zhou Z; Wang P
Biochem Biophys Res Commun; 2010 Aug; 399(2):274-8. PubMed ID: 20655295
[TBL] [Abstract][Full Text] [Related]
11. Early growth response-1 is involved in foam cell formation and is upregulated by the TLR9-MyD88-ERK1/2 pathway.
Kim JS; Park DW; Lee HK; Kim JR; Baek SH
Biochem Biophys Res Commun; 2009 Dec; 390(2):196-200. PubMed ID: 19737531
[TBL] [Abstract][Full Text] [Related]
12. The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity.
Sen G; Flora M; Chattopadhyay G; Klinman DM; Lees A; Mond JJ; Snapper CM
Cell Immunol; 2004; 232(1-2):64-74. PubMed ID: 15922717
[TBL] [Abstract][Full Text] [Related]
13. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
14. Specific siRNA downregulated TLR9 and altered cytokine expression pattern in macrophage after CpG DNA stimulation.
Qiao B; Li B; Yang X; Zhang H; Chu Y; Wang Y; Xiong S
Cell Mol Immunol; 2005 Apr; 2(2):130-5. PubMed ID: 16191419
[TBL] [Abstract][Full Text] [Related]
15. Bovine toll-like receptor 9: a comparative analysis of molecular structure, function and expression.
Griebel PJ; Brownlie R; Manuja A; Nichani A; Mookherjee N; Popowych Y; Mutwiri G; Hecker R; Babiuk LA
Vet Immunol Immunopathol; 2005 Oct; 108(1-2):11-6. PubMed ID: 16098606
[TBL] [Abstract][Full Text] [Related]
16. Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens.
Andersen JM; Al-Khairy D; Ingalls RR
Biol Reprod; 2006 May; 74(5):824-31. PubMed ID: 16421230
[TBL] [Abstract][Full Text] [Related]
17. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.
Väisänen MR; Väisänen T; Jukkola-Vuorinen A; Vuopala KS; Desmond R; Selander KS; Vaarala MH
Prostate; 2010 Jun; 70(8):817-24. PubMed ID: 20054821
[TBL] [Abstract][Full Text] [Related]
18. A combination of Lox-1 and Nox1 regulates TLR9-mediated foam cell formation.
Lee JG; Lim EJ; Park DW; Lee SH; Kim JR; Baek SH
Cell Signal; 2008 Dec; 20(12):2266-75. PubMed ID: 18817866
[TBL] [Abstract][Full Text] [Related]
19. Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility: role of toll-like receptor 9.
Knuefermann P; Schwederski M; Velten M; Krings P; Ehrentraut H; Rüdiger M; Boehm O; Fink K; Dreiner U; Grohé C; Hoeft A; Baumgarten G; Koch A; Zacharowski K; Meyer R
Cardiovasc Res; 2008 Apr; 78(1):26-35. PubMed ID: 18194990
[TBL] [Abstract][Full Text] [Related]
20. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
